These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18050723)

  • 1. [Postoperative rehabilitation of patients with dyshormonal hyperplasia of the prostate].
    Georgiadi-Avdienko KA; Mutchaev KIu; Kurtaev OSh
    Vopr Kurortol Fizioter Lech Fiz Kult; 2007; (5):26-9. PubMed ID: 18050723
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
    Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
    Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hormone-resistant prostate cancer.
    Gibbons RP
    Prog Clin Biol Res; 1989; 303():337-45. PubMed ID: 2674995
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 7. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.
    Cox RA; Sundar S
    Br J Cancer; 2008 Jan; 98(1):238-9. PubMed ID: 18182981
    [No Abstract]   [Full Text] [Related]  

  • 10. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving effective risk-factor modification in urological patients.
    Kirby R; Kirby M
    BJU Int; 2008 Apr; 101(7):793-4. PubMed ID: 18321313
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment.
    Carter HB
    Urology; 2009 Jul; 74(1):183; aurhor reply 183-4. PubMed ID: 19567300
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA era.
    Eisenberger MA
    Urol Oncol; 2008; 26(4):406-7. PubMed ID: 18593618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.